Feng Zhang's latest gene editing trawl reels in 188 new CRISPR systems - Endpoints News endpts.com Submitted by endpointsnews6292 on November 28, 2023 at 4:24 PM in science No comments 41
Bristol Myers and 2seventy bio say FDA delayed CAR-T therapy decision - Endpoints News endpts.com Submitted by endpointsnews6292 on November 21, 2023 at 4:16 PM in business No comments 27
FDA's Janet Woodcock to retire in early 2024 - Endpoints News endpts.com Submitted by endpointsnews6292 on November 17, 2023 at 6:57 PM in business No comments 25
Q32 Bio to take Homology Medicines' Nasdaq spot to fund PhII trials in autoimmune, inflammatory conditions - Endpoints News endpts.com Submitted by endpointsnews6292 on November 17, 2023 at 1:44 PM in business No comments 60
In a world first, Vertex, CRISPR win UK approval for CRISPR-edited therapy to treat sickle cell disease, beta-thalassemia - Endpoints News endpts.com Submitted by endpointsnews6292 on November 17, 2023 at 11:15 AM in news No comments 55
Verve won trial success with a gene-editing milestone. Why don't investors like it? - Endpoints News endpts.com Submitted by endpointsnews6292 on November 15, 2023 at 4:45 PM in health No comments 54
Anthos' blood thinner cuts the risk of bleeding amid race to develop safer anticoagulants - Endpoints News endpts.com Submitted by endpointsnews6292 on November 14, 2023 at 4:12 PM in health No comments 55
Alnylam's longer-term RNAi treatment lowers blood pressure in mid-stage study - Endpoints News endpts.com Submitted by endpointsnews6292 on November 14, 2023 at 9:27 AM in news No comments 50
CAR-T cell therapy biotech CARGO Therapeutics prices $281M IPO - Endpoints News endpts.com Submitted by endpointsnews6292 on November 11, 2023 at 1:15 AM in business No comments 32
AstraZeneca pays $25M upfront, $80M equity investment into Cellectis for gene and cell therapy pact - Endpoints News endpts.com Submitted by endpointsnews6292 on November 2, 2023 at 11:20 AM in business No comments 55
Pfizer details mRNA flu vaccine data, but revises timeline - Endpoints News endpts.com Submitted by endpointsnews6292 on November 1, 2023 at 11:46 AM in health No comments 18
Lilly makes another move for Verve's genetic medicines, this time buying Beam's opt-in rights - Endpoints News endpts.com Submitted by endpointsnews6292 on November 1, 2023 at 10:00 AM in business No comments 45
FDA approves Junshi, Coherus’ PD-1 toripalimab for nasopharyngeal carcinoma - Endpoints News endpts.com Submitted by endpointsnews6292 on October 31, 2023 at 11:28 AM in business No comments 11
Sanofi will spin out consumer unit, putting weight behind R&D efforts: 'I have to invest in the science now' - Endpoints News endpts.com Submitted by endpointsnews6292 on October 28, 2023 at 5:30 AM in business No comments 18
'Excited to be back': Roche's sequel to failed Alzheimer's antibody looks promising in early study - Endpoints News endpts.com Submitted by endpointsnews6292 on October 26, 2023 at 7:18 PM in health No comments 37
Grifols' Alzheimer's vaccine appears safe, but efficacy unclear, in PhII study - Endpoints News endpts.com Submitted by endpointsnews6292 on October 25, 2023 at 10:31 PM in health No comments 49
Biogen, GSK, Novo Nordisk and five other biopharmas land on annual list of best inventions for 2023 - Endpoints News endpts.com Submitted by endpointsnews6292 on October 25, 2023 at 6:49 PM in health No comments 1
Amgen to cut 350 staffers following $28B Horizon takeover - Endpoints News endpts.com Submitted by endpointsnews6292 on October 25, 2023 at 6:25 PM in business No comments 45
Padcev-Keytruda sets new standard in bladder cancer as Seagen and Astellas move toward full approval: #ESMO23 - Endpoints News endpts.com Submitted by endpointsnews6292 on October 24, 2023 at 5:30 AM in business No comments 56
ESMO embargo break leads cancer conference to release data for Bristol Myers, J&J, Novartis, AstraZeneca - Endpoints News endpts.com Submitted by endpointsnews6292 on October 18, 2023 at 7:53 PM in business No comments 48
Gilead spends $100M to partner with Assembly Bio on antivirals for hepatitis, herpes - Endpoints News endpts.com Submitted by endpointsnews6292 on October 18, 2023 at 11:00 AM in business No comments 58
Nuvalent's $300M offering; Spark ends epilepsy deal; A small IPO - Endpoints News endpts.com Submitted by endpointsnews6292 on October 17, 2023 at 2:05 PM in business No comments 59
Omeros drug fails a PhIII kidney trial, stock nearly halved - Endpoints News endpts.com Submitted by endpointsnews6292 on October 17, 2023 at 1:33 PM in business No comments 28
Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial - Endpoints News endpts.com Submitted by endpointsnews6292 on October 14, 2023 at 2:00 PM in business No comments 10
Moderna's new Covid-19 vaccine analysis 'giving weight' to annual boosting interval, company says - Endpoints News endpts.com Submitted by endpointsnews6292 on October 12, 2023 at 6:13 PM in health No comments 3